Cellectar Presents Phase 2b Iopofosine Data in BTK-Inhibitor-Refractory Patients

A subset analysis reported an 87.5% ORR, 79.2% MRR and 100% CBR, with median duration of response of 16 months. The company also reported initiation and site selections for a Phase 3 confirmatory randomized trial.